Novartis AG NVS
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 10.03B | 12.76B | 13.53B | 13.98B | 14.39B |
| Total Depreciation and Amortization | 4.87B | 4.82B | 4.78B | 4.74B | 4.73B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.11B | 3.10B | 2.97B | 3.48B | 2.98B |
| Change in Net Operating Assets | -3.69B | -2.29B | -2.11B | -3.06B | -1.03B |
| Cash from Operations | 17.33B | 18.39B | 19.18B | 19.14B | 21.07B |
| Capital Expenditure | -1.67B | -1.63B | -1.64B | -1.55B | -1.50B |
| Sale of Property, Plant, and Equipment | 32.00M | 33.00M | 8.00M | 13.00M | 59.00M |
| Cash Acquisitions | -17.05B | -16.04B | -14.96B | -2.92B | -2.18B |
| Divestitures | 93.00M | -13.00M | -86.00M | -88.00M | 85.00M |
| Other Investing Activities | -96.00M | -159.00M | -268.00M | -338.00M | -2.27B |
| Cash from Investing | -18.69B | -17.81B | -16.94B | -4.88B | -5.81B |
| Total Debt Issued | 18.98B | 19.12B | 17.78B | 6.67B | 1.52B |
| Total Debt Repaid | -2.79B | -2.67B | -3.25B | -4.24B | -2.48B |
| Issuance of Common Stock | 18.00M | 20.00M | 26.00M | 27.00M | 23.00M |
| Repurchase of Common Stock | -6.25B | -6.86B | -8.37B | -9.21B | -10.49B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -9.07B | -9.07B | -8.68B | -7.82B | -7.82B |
| Other Financing Activities | -111.00M | -91.00M | -239.00M | -294.00M | -298.00M |
| Cash from Financing | 778.00M | 453.00M | -2.74B | -14.87B | -19.55B |
| Foreign Exchange rate Adjustments | -98.00M | -81.00M | 319.00M | 576.00M | 226.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -686.00M | 960.00M | -189.00M | -24.00M | -4.05B |